BIIB Price Prediction Next Week
Technical Analysis: BIIB's recent price action shows a bearish trend with the stock trading below all major moving averages (SMA 5: 137.66, SMA 20: 141.56, SMA 200: 188.29). The RSI-14 at 47.08 indicates neutral momentum but trending downward.
News Impact & Fundamental Catalysts:
- Recent partnership with Stoke Therapeutics for Dravet syndrome treatment, with $165 million upfront payment and potential milestone payments up to $385 million
- Q4 2024 earnings showed core pharmaceutical business growth for first time in four years, driven by new product launches including Leqembi, Skyclarys, Zurzuvae, and Qalsody
- Leqembi showing strong growth in Asia, while Skyclarys doubled patient numbers
Price Prediction for Next Week: Based on technical indicators and Fibonacci levels:
- Resistance levels: R1: 142.64, R2: 146.22
- Support levels: S1: 131.05, S2: 127.47
- Current price: 140.64
Expected price range for next week: 138-144
Trading Recommendation: SELL Rationale:
- Price trading below all major moving averages indicating bearish trend
- MACD showing negative momentum (-2.72)
- Despite positive news on partnerships, technical indicators suggest continued downward pressure
- Stock has been underperforming broader market indices
- Fibonacci levels suggest limited upside potential with strong resistance at 142.64
Target exit price: 131.05 (S1 level) Stop loss: 146.22 (R2 level)
BIIB Similar Chart Price Prediction
The price of BIIB is predicted to go up -9.16%, based on the high correlation periods with LOGI. The similarity of these two price pattern on the periods is 93.17%.
BIIB
LOGI
Down: -9.16%Similarity: 93.17%
BIIB Revenue Forecast
BIIB EPS Forecast
BIIB FAQs
What is bull’s view on BIIB?
What is bear's view on BIIB?
What is BIIB revenue forecast for next quarter？
What is BIIB eps forecast for next quarter？
BIIB VS S&P500
Biogen leads the $20 billion global MS market with Avonex, Plegridy, Tysabri, and Tecfidera. The launch of Vumerity partly protects Tecfidera sales from generic headwinds in the U.S.
Biogen receives royalties and profit share from Roche on MS drug Ocrevus and multiple CD20-targeted cancer therapies, boosting profitability.
Biogen's neurology portfolio outside of MS, including Leqembi in Alzheimer's, should help diversify revenue and boost sales growth.
BIIB Analyst's Forecast
Salveen Richter
Goldman Sachs
Strong Buy
2025-02-13
Price Target
$281 → $245
Upside
+77.32%
Goldman Sachs lowered the firm's price target on Biogen to $245 from $281 but keeps a Buy rating on the shares. The firm cites the company's FY25 guidance indicating a mid-single digit y/y revenue decline and lower than expected EPS on FX headwinds, the analyst tells investors in a research note. The firm adds that it expects Biogen shares to remain range bound amid execution on BD/M&A, where the management is interested in rare disease/immunology/potentially neurology and smaller/earlier-stage deals as well as the recognition of late-stage pipeline value.
Geoff Meacham
Citigroup
Hold
2025-02-13
Price Target
$160 → $145
Upside
+4.94%
Mohit Bansal
Wells Fargo
Hold
2025-02-13
Price Target
$165 → $140
Upside
+1.32%
